Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 1:23 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,471 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Recruiting Phase 3 Interventional

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

NCT07754461
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, Survodutide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
71
States / cities
Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Completed Phase 2 Interventional Results available

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

NCT05213624
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Completed Not applicable Interventional

Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors

NCT00662103
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Psychosocial Effects of Cancer and Its Treatment
Interventions
exercise intervention, laboratory biomarker analysis, questionnaire administration, survey administration, assessment of therapy complications, fatigue assessment and management, management of therapy complications, psychosocial assessment and care
Behavioral · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
65 Years to 120 Years · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Nov 2, 2026, 1:23 AM EST
Completed Not applicable Interventional

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

NCT00645918
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
clopidogrel, placebo
Drug
Lead sponsor
Accumetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
72
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Nov 2, 2026, 1:23 AM EST
Completed Phase 1 Interventional

AZD9496 First Time in Patients Ascending Dose Study

NCT02248090
View directory record Official record
Conditions
ER+ HER2- Advanced Breast Cancer
Interventions
AZD9496
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Sarasota, Florida • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Nov 2, 2026, 1:23 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

To Assess the Safety of a Sunscreen Product

NCT02803320
View directory record Official record
Conditions
Sunscreening Agents
Interventions
SPF 50 Y65 110 (BAY 987516)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Nov 2, 2026, 1:23 AM EST
Completed Phase 2 Interventional Results available

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

NCT04015518
View directory record Official record
Conditions
Palmoplantar Pustulosis (PPP)
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 2, 2026, 1:23 AM EST
Completed Not applicable Interventional Results available

Feasibility Studies of Personalized Closed Loop

NCT04203823
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Cloud-based Digital Twin and Meal Prediction algorithms
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Loma Linda, California • Walnut Creek, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Nov 2, 2026, 1:23 AM EST
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

New In Situ Model Design for Caries and Erosion

NCT07849270
View directory record Official record
Conditions
Caries, Erosive Tooth Wear
Interventions
0 ppm fluoride toothpaste, 250 ppm fluoride toothpaste (dose-response control), 1150 ppm fluoride toothpaste, Mandibular intraoral appliance
Drug · Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Healthy Participants

NCT07701083
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Eloralintide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Not yet recruiting Not applicable Interventional

RE-FIT (Remote Exercise for Physical Function in WTC Responders With Prostate Cancer)

NCT07440641
View directory record Official record
Conditions
Prostate Cancer
Interventions
Remote Supervised Exercise Program
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
55 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Recruiting Not applicable Interventional

A Multi Center Study Testing a New Implant for Adults With Severe Emphysema

NCT07119229
View directory record Official record
Conditions
Emphysema or COPD, Emphysema, COPD
Interventions
Implantable Artificial Bronchus
Device
Lead sponsor
Pulmair Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Completed Phase 2 Interventional

A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin")

NCT04258761
View directory record Official record
Conditions
Submental Fat
Interventions
10XB-101 Solution for Injection
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Nov 2, 2026, 1:23 AM EST
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

NCT02864082
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%
Drug
Lead sponsor
Patagonia Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Nov 2, 2026, 1:23 AM EST
Not listed Phase 1 Interventional

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

NCT03921879
View directory record Official record
Conditions
Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Follicular, Lymphoma, Peripheral T-Cell, Lymphoma, Hodgkin
Interventions
OT-82 Dose Escalation, OT-82 Dose Expansion
Drug
Lead sponsor
Oncotartis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Birmingham, Alabama • Duarte, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Nov 2, 2026, 1:23 AM EST
Completed Phase 2 Interventional

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT06335303
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 1819479, Placebo matching BI 1819479
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Recruiting Phase 4 Interventional

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

NCT06145373
View directory record Official record
Conditions
Hemophilia A
Interventions
Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Los Angeles, California • Flowood, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

PATHFINDER 2: A Multi-Cancer Early Detection Study

NCT05155605
View directory record Official record
Conditions
Early Detection of Cancer, Cancer
Interventions
Multi-Cancer Early Detection Test
Device
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
50 Years and older
Enrollment
35,883 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
55
States / cities
Auburn, California • Davis, California • Elk Grove, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

NCT06360094
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
BI 1839100, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

SEPA+PrEP-Women Pilot Trial for HIV Prevention Among Women at Risk for HIV

NCT07864766
View directory record Official record
Conditions
HIV Infections
Interventions
SEPA+PrEP Women
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 2, 2026, 1:23 AM EST
Completed Phase 1 Interventional

Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients

NCT00562003
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer
Interventions
Tenckhoff Catheter placement, Ad5-delta24RGD
Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Nov 2, 2026, 1:23 AM EST
Completed Not applicable Interventional

Occupational Therapy Driving Intervention for Returning Combat Veterans.

NCT02764983
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Post Traumatic Stress Disorder (PTSD)
Interventions
Driving Behavior Interview, Fitness-to-Drive Screening Measure, Clinical Driving Assessment, Propensity for Angry Driving Scale, Community Integration Questionnaire, Satisfaction with Life Questionnaire, Driving simulator evaluation, Focus Group Discussion Interview Guide
Behavioral · Other · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Nov 2, 2026, 1:23 AM EST
Completed Phase 1 Interventional

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART

NCT01378156
View directory record Official record
Conditions
HIV-1 Infection
Interventions
JS7 plasmid DNA and MVA62B vaccine
Biological
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Nov 2, 2026, 1:23 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

NCT01440569
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
COBI, DRV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Nov 2, 2026, 1:23 AM EST